To the full analysis
Buyback calculator for Arcus Biosciences
Arcus Biosciences stock: key metrics
RCUSArcus Biosciences had an operating margin of −156.3% and a return on invested capital (ROIC) of −33.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2016 | no data | no data | no data |
| 2017 | 100.0% | −3,782.1% | −3,756.7% |
| 2018 | 100.0% | −656.8% | −593.7% |
| 2019 | 100.0% | −591.4% | −564.7% |
| 2020 | 100.0% | −159.0% | −157.7% |
| 2021 | 100.0% | 14.1% | 13.8% |
| 2022 | 100.0% | −250.0% | −238.4% |
| 2023 | 100.0% | −290.6% | −262.4% |
| 2024 | 100.0% | −127.9% | −109.7% |
| 2025 | 96.0% | −156.3% | −142.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2016 | −18.1% | −13.8% | −16.4% |
| 2017 | −34.5% | −30.0% | −27.9% |
| 2018 | −21.1% | −19.9% | −18.0% |
| 2019 | −51.7% | −32.0% | −41.7% |
| 2020 | −24.5% | −23.5% | −15.9% |
| 2021 | 6.3% | 5.0% | 3.3% |
| 2022 | −40.6% | −17.1% | −19.9% |
| 2023 | −66.5% | −26.0% | −28.0% |
| 2024 | −58.4% | −28.4% | −24.6% |
| 2025 | −55.9% | −33.3% | −31.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2023)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.